SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with common diseases, today announced that the first participants have been dosed in the company’s Phase 1 clinical trial evaluating MZE782 in healthy volunteers.

南旧金山--（商业新闻短讯）--Maze Therapeutics是一家临床阶段的生物制药公司，利用人类遗传学的力量为患有常见疾病的患者开发新型小分子精密药物，今天宣布，该公司在健康志愿者中评估MZE782的第一阶段临床试验中，首批参与者已经服用。

MZE782 is a potentially first-in-class, oral, small molecule targeting the solute transporter, SLC6A19. MZE782 has the potential to initially address approximately five million of the approximately 37 million chronic kidney disease (CKD) patients in the United States who have inadequate responses to currently available CKD therapies..

MZE782是靶向溶质转运蛋白SLC6A19的潜在一流口服小分子。MZE782有可能最初解决美国约3700万慢性肾病（CKD）患者中约500万人的问题，这些患者对目前可用的CKD疗法反应不足。。

“CKD is a serious and progressive disease that impacts millions of people in the United States, with standard therapies focusing on slowing disease progression, rather than targeting the underlying genetic drivers of disease,” said Harold Bernstein, M.D., Ph.D., president, R&D, and chief medical officer of Maze.

梅兹医学博士、研发总裁兼首席医疗官哈罗德·伯恩斯坦（HaroldBernstein）表示：“CKD是一种严重且进行性的疾病，影响着美国数百万人，标准疗法的重点是减缓疾病进展，而不是针对疾病的潜在遗传驱动因素。”。

“Using our Compass platform, we identified the solute transporter SLC6A19 as a promising treatment target to address a subset of patients with CKD and have designed MZE782 to phenocopy the kidney protective effects of SLC6A19 protective variants. MZE782 has the potential to be a first-in-class therapy to treat approximately five million patients that do not respond to currently available treatments.

“使用我们的Compass平台，我们将溶质转运蛋白SLC6A19确定为一种有前途的治疗靶点，以解决CKD患者的一部分，并设计了MZE782来表型分析SLC6A19保护性变体的肾脏保护作用。MZE782有可能成为治疗约500万对目前可用治疗无反应的患者的一流疗法。

This is our third clinical program, and the initiation of this first-in-human clinical trial is an important step forward in understanding the therapeutic potential of MZE782. The trial is designed to not only evaluate its safety and tolerability, but also to provide pharmacokinetic and pharmacodynamic insights using a non-invasive biomarker intended to optimize the design of future clinical trials in patients.

这是我们的第三个临床计划，这项首次人体临床试验的启动是了解MZE782治疗潜力的重要一步。该试验不仅旨在评估其安全性和耐受性，还旨在使用非侵入性生物标志物提供药代动力学和药效学见解，以优化患者未来临床试验的设计。

We expect to provide initial results of this clinical trial, including potential proof of mechanism utilizing these biomarkers, in the second half of 2025.”.

我们预计在2025年下半年提供该临床试验的初步结果，包括利用这些生物标志物的潜在机制证据。”。

The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled single and multiple ascending dose study in healthy volunteers designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics as measured by urinary excretion of known SLC6A19 cargo, e.g., neutral amino acids..

第一阶段临床试验是一项针对健康志愿者的随机、双盲、安慰剂对照单剂量和多剂量递增研究，旨在评估已知SLC6A19货物（例如中性氨基酸）的尿排泄量所测量的安全性、耐受性、药代动力学和药效学。。

Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens, or as an alternative option for those patients who do not adequately respond to the current standard of care..

除了用作潜在的独立疗法外，MZE782还可以与标准护理相结合，为患者提供显着的益处，包括作为当前批准方案的补充治疗，或作为对当前护理标准反应不足的患者的替代选择。。

About Maze Therapeutics

关于迷宫疗法

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with common diseases, with a focus on renal, cardiovascular and related metabolic, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups.

Maze Therapeutics是一家临床阶段的生物制药公司，利用人类遗传学的力量为患有常见疾病的患者开发新型小分子精密药物，重点关注肾脏，心血管和相关代谢，包括肥胖。该公司正在利用其Compass平台推进一条管道，该平台提供了对疾病遗传变异的见解，并将其与特定患者群体中驱动疾病的生物途径联系起来。

The company’s pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. For more information, please visit mazetx.com, or follow us on LinkedIn and X (formerly Twitter)..

该公司的管道由两个全资领先项目MZE829和MZE782领导，每个项目都代表了一种基于精准医学的慢性肾脏疾病新方法。有关更多信息，请访问mazetx.com，或在LinkedIn和X（以前的Twitter）上关注我们。。